JP2022062170A5 - - Google Patents

Download PDF

Info

Publication number
JP2022062170A5
JP2022062170A5 JP2022015456A JP2022015456A JP2022062170A5 JP 2022062170 A5 JP2022062170 A5 JP 2022062170A5 JP 2022015456 A JP2022015456 A JP 2022015456A JP 2022015456 A JP2022015456 A JP 2022015456A JP 2022062170 A5 JP2022062170 A5 JP 2022062170A5
Authority
JP
Japan
Prior art keywords
once
pharmaceutical composition
year
composition according
arc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022015456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022062170A (ja
Filing date
Publication date
Priority claimed from JP2020153037A external-priority patent/JP7021314B2/ja
Application filed filed Critical
Publication of JP2022062170A publication Critical patent/JP2022062170A/ja
Publication of JP2022062170A5 publication Critical patent/JP2022062170A5/ja
Priority to JP2023174548A priority Critical patent/JP7559175B6/ja
Pending legal-status Critical Current

Links

JP2022015456A 2016-02-12 2022-02-03 Hivおよびエイズの治療および予防方法 Pending JP2022062170A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174548A JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662294576P 2016-02-12 2016-02-12
US62/294,576 2016-02-12
US201662297657P 2016-02-19 2016-02-19
US62/297,657 2016-02-19
JP2020153037A JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020153037A Division JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174548A Division JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Publications (2)

Publication Number Publication Date
JP2022062170A JP2022062170A (ja) 2022-04-19
JP2022062170A5 true JP2022062170A5 (https=) 2022-07-14

Family

ID=58057333

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018541685A Active JP6810972B2 (ja) 2016-02-12 2017-02-10 Hivおよびエイズの治療および予防方法
JP2020153037A Active JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法
JP2022015456A Pending JP2022062170A (ja) 2016-02-12 2022-02-03 Hivおよびエイズの治療および予防方法
JP2023174548A Active JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018541685A Active JP6810972B2 (ja) 2016-02-12 2017-02-10 Hivおよびエイズの治療および予防方法
JP2020153037A Active JP7021314B2 (ja) 2016-02-12 2020-09-11 Hivおよびエイズの治療および予防方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174548A Active JP7559175B6 (ja) 2016-02-12 2023-10-06 Hivおよびエイズの治療および予防方法

Country Status (37)

Country Link
US (4) US10537589B2 (https=)
EP (1) EP3413897B1 (https=)
JP (4) JP6810972B2 (https=)
KR (4) KR20220126787A (https=)
CN (2) CN113509480A (https=)
AU (3) AU2017217656B2 (https=)
BR (1) BR112018016349A2 (https=)
CA (1) CA3013473C (https=)
CL (1) CL2018002150A1 (https=)
DK (1) DK3413897T3 (https=)
DO (1) DOP2018000183A (https=)
EA (1) EA201891814A1 (https=)
ES (1) ES2953535T3 (https=)
FI (1) FI3413897T3 (https=)
GE (2) GEP20217231B (https=)
HR (1) HRP20230935T1 (https=)
HU (1) HUE063532T2 (https=)
IL (1) IL260874B2 (https=)
JO (1) JOP20170038B1 (https=)
LT (1) LT3413897T (https=)
MD (1) MD3413897T2 (https=)
MX (3) MX390604B (https=)
MY (1) MY197090A (https=)
NI (1) NI201800083A (https=)
NZ (1) NZ745065A (https=)
PH (1) PH12018501712A1 (https=)
PL (1) PL3413897T3 (https=)
PT (1) PT3413897T (https=)
RS (1) RS64448B1 (https=)
SG (1) SG11201806783WA (https=)
SI (1) SI3413897T1 (https=)
SV (1) SV2018005733A (https=)
TN (1) TN2018000267A1 (https=)
TW (2) TWI911551B (https=)
UA (1) UA126375C2 (https=)
WO (1) WO2017139519A1 (https=)
ZA (1) ZA201805073B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
US12297224B2 (en) * 2018-07-02 2025-05-13 Henan Genuine Biotech Co., Ltd. Crystal form, preparation method, and application of 4'-substituted nucleoside
EP3823632B1 (en) * 2018-07-17 2025-10-29 Merck Sharp & Dohme LLC Efda in combination with doravirine for use in treating f227c mutated hiv infections
JP7530899B2 (ja) * 2018-12-20 2024-08-08 メルク・シャープ・アンド・ドーム・エルエルシー Nrtti化合物の新規結晶形態
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
AU2020231934B2 (en) * 2019-03-06 2023-04-20 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in HIV therapy
WO2021021717A1 (en) 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0831852B1 (en) * 1995-06-07 2006-11-29 Emory University Nucleosides with anti-hepatitis b virus activity
EA012844B1 (ru) 2003-02-19 2009-12-30 Йельский Университет Аналоги противовирусных нуклеозидов и способы лечения вирусных инфекций, в частности вич-инфекций
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2009126293A2 (en) * 2008-04-11 2009-10-15 Yale University Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase
WO2012099630A1 (en) * 2011-01-20 2012-07-26 University Of Rochester Compositions and methods for treating or preventing a retrovirus infection
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
CN108289931B (zh) 2015-09-23 2022-10-11 默沙东公司 4’-取代的核苷逆转录酶抑制剂及其制备
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
KR102272235B1 (ko) * 2016-05-12 2021-07-01 머크 샤프 앤드 돔 코포레이션 항바이러스제의 전달을 위한 약물 전달 시스템
US20190388336A1 (en) * 2016-06-20 2019-12-26 Merck Sharp & Dohme Corp. Drug Delivery System for the Delivery of Antiviral Agents
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
CA3150272A1 (en) * 2019-08-13 2021-02-18 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents
CN115843259A (zh) * 2020-05-05 2023-03-24 默沙东有限责任公司 用于递送抗病毒剂和避孕药的药物递送系统
US20230310309A1 (en) * 2020-08-25 2023-10-05 Merck Sharp & Dohme Llc Injectable depot compositions for the delivery of antiviral agents

Similar Documents

Publication Publication Date Title
JP2022062170A5 (https=)
JP2022009090A5 (https=)
JP2021001189A5 (https=)
JP2024133475A5 (https=)
RU2329050C2 (ru) Комбинация ингибиторов цитохром-р450-зависимых протеаз
HRP20230935T1 (hr) Postupci za liječenje i profilaksu hiv-a i aids-a
JP2020505423A5 (https=)
JP2019536805A5 (https=)
JP2018513188A5 (https=)
RU2010104848A (ru) Кристаллическая форма 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
JP2019517542A5 (https=)
JP2016185995A5 (https=)
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
JP2017514911A5 (https=)
RU2016114098A (ru) Новое производное аналога инсулина
JP2018530578A5 (https=)
JP2020523356A5 (https=)
RU2494736C2 (ru) Комбинация, включающая паклитаксел, для лечения рака яичников
JPWO2020261093A5 (https=)
JP2021004249A5 (https=)
JPWO2020257671A5 (https=)
CN104622927A (zh) 外用消炎粉
JP2019531286A5 (https=)
JP2019535830A5 (https=)
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты